Anthrax is a serious disease that can affect both animals and humans. It is caused by bacteria called Bacillus anthracis. People can get anthrax from contact with infected animals, wool, meat, or hides.Anthrax vaccine protects against anthrax disease. Anthrax vaccine was licensed in 1970.Based on limited but sound evidence, the vaccine protects against both cutaneous (skin) and inhalation anthrax.
Scope of the Report:The classification of Anthrax Vaccines includes Live Vaccines and Cell free PA Vaccines, and the revenue proportion of Live Vaccines in 2016 is about 43%.
Anthrax Vaccines are widely used for human and animal. The most proportion of Anthrax Vaccines is used for animal, and the consumption proportion is about 95.1% in 2016.
South America region is the largest supplier of Anthrax Vaccines, with a production market share nearly 34.7% in 2016. Europe is the second largest supplier of Anthrax Vaccines, enjoying production market share nearly 17.6% in 2016.
South America is the largest sales place, with a sales market share nearly 39.3% in 2016. Following South America, Europe is the second largest sales place with the sales market share of 19.1%.
Along with the development of China 's Agricultural technology, there is a lot Chinese local manufacturer can produce Anthrax Vaccines, with the increasing demand, more and more manufactures will go into Anthrax Vaccines industry.
Market competition is intense. Emergent BioSolutions is the major manufacturer of Anthrax Vaccines used for human, Merial, Merck, Zoetis, Bayer Sanidad Animal,Colorado Serum, etc. are is the major manufacturer of Anthrax Vaccines used for animal, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.
The worldwide market for Anthrax Vaccines is expected to grow at a CAGR of roughly 7.5% over the next five years, will reach 720 million US$ in 2026, from 500 million US$ in 2020, according to a new Our study.
This report focuses on the Anthrax Vaccines in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers Emergent BioSolutions
Merial
Merck
ZoetisÊ
Bayer Sanidad Animal
Colorado Serum
PharmAthene
Tiankang
BiogŽnesis-Bago
CAVAC
Rosenbusch
Agrovet
Vecol
CVCRI
IVPM
Prondil
CDV
Indian Immunologicals
Botswana Vaccine Institute
Ceva SantŽ Animale
Intervac
JOVAC
Market Segment by Regions, regional analysis covers North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers LiveÊVaccines
CellÊfreeÊPAÊVaccines
Market Segment by Applications, can be divided into HumanÊUse
AnimalÊUse
The content of the study subjects, includes a total of 15 chapters:Chapter 1, to describe Anthrax Vaccines product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Anthrax Vaccines, with price, sales, revenue and global market share of Anthrax Vaccines in 2018 and 2019.
Chapter 3, the Anthrax Vaccines competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Anthrax Vaccines breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Anthrax Vaccines market forecast, by regions, type and application, with sales and revenue, from 2020 to 2026.
Chapter 13, 14 and 15, to describe Anthrax Vaccines sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Frequently Asked Questions
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
- By Type
- By Application
- By Region
- By Country
- By Manufacturer
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
